Alterations in p-PERK, p-eIF2α and CHOP are seen in patients with Parkinson’s (PD) [31,37] and Alzheimer’s diseases (AD) [38–40], Huntington’s disease (HD) [41,42], and ALS [28,43]. Here, EIF2A is linked to juvenile Huntington disease.